ACQUITY UPC 2 ACQUITY UPC 2 A A+D3 D ml E 10 ml K μm K μm PDA ACQUITY UPC 2 BEH mm, 1.7 μm ACQUITY UPC 2 HSS C 18 SB 3.
|
|
|
- みそら ちゅうか
- 5 years ago
- Views:
Transcription
1 UPC 2 Andrew Aubin Waters Corporation, Milford, MA, USA Waters ACQUITY UPC 2TM 6 tert- UltraPerformance Convergence Chromatography TM UPC 2 ACQUITY UPC 2 1 A A D3 E D3 K1 K2 UPC 2 A E K1 ACQUITY UPC 2 ACQUITY UPC 2 ACQUITY UPC 2 PDA Empowe TM 3 1 / A 10,000 IU A A+D3 10,000 IU A 2000 IU D3 D IU D3 E 400 IU E 6 1 K1 100 µg K2 50 µg UPC 2 E A D3 K1 K2 1
2 ACQUITY UPC 2 ACQUITY UPC 2 A A+D3 D ml E 10 ml K μm K μm PDA ACQUITY UPC 2 BEH mm, 1.7 μm ACQUITY UPC 2 HSS C 18 SB mm, 1.8 μm ACQUITY UPC 2 HSS C 18 SB mm, 1.8 μm Empower3 A A A ABPR 2176 psi CO 2 / 0.2% 97:3 90: A A trans-vitamin A palmitate cis-vitamin A palmitate A 2 UPC 2
3 A/B ABPR ACQUITY UPC 2 HSS C 18 SB, mm, 1.8 μm 2.0 ml/min 97 : 3 90 : 10 3 A CO 2 / B 0.2 % UV 320 nm nm 1 μl 2176 psi 50 2 A Vitamin A acetate Vitamin A palmitate Retinol A A UPC 2 3
4 A+D3 A A D3 A D D trans-vitamin A palmitate cholecalciferol cis-vitamin A palmitate cholecalciferol A+D3 4 UPC 2
5 CO 2 / 0.2% 99:1 90: A/B ABPR ACQUITY UPC 2 HSS C 18 SB, mm, 1.8 μm 1.0 ml/min 99 : 1 90 : A CO 2 / B 0.2% UV 263 nm nm 1 μl 2176 psi 50 3 A D3 D3 D3 3 A+D3 D cholecalciferol D3. UPC 2 5
6 E E 4 (d-, d-, d-, d- ) 90 5 CO 2 / 0.2% 98: α-tocopherol γ-tocopherol δ-tocopherol 0.26 β-tocopherol E A/B ABPR ACQUITY UPC 2 BEH, mm, 1.7 μm 2.5 ml/min 98 : 2 95 : A CO 2 / B UV 293 nm nm 1 μl 1885 psi 50 4 E 6 UPC 2
7 K1 K1 6 CO 2 / / = 1:1 = 99 : 1 RS>2.0 7 UV 246 nm 2 K trans-phylloquinone cis-phylloquinone K1 ACQUITY UPC 2 HSS C 18 SB, mm, 1.8 μm 1.5 ml/min A / B = 99 : 1 A/B A CO 2 / B / UV 248 nm nm 2 μl ABPR 1885 psi 50 5 K1 UPC 2 7
8 Peak trans-phylloquinone Peak cis-phylloquinone nm K UV 8 UPC 2
9 K2 K2 MK MK-3 MK-14 CO 2 / = 95 : MK-7 MK menaquinone-7 (MK7) K2 A/B ABPR ACQUITY UPC 2 HSS C 18 SB, mm, 1.8 μm 3.0 ml/min 95% A 5% B A CO 2 / B UV 248 nm nm 1 μl 1885 psi 50 6 K2 UPC 2 9
10 ACQUITY UPC 2 6 A E K TEL FAX F TEL FAX Waters Waters Corporation ACQUITY UPC 2 UltraPerformance Convergence Chromatography UPC 2 Empower The Science of What s Possible Waters Corporation 2012 Waters Corporation. Printed in Japan JA PDF
LC ACQUITY UPLC H-Class Bio TUV Sigma, mg/ml 0.01 N 276 nm μl 0.4 ml/min L g/l / 99% / 65/15/20 v/v/v 10% 10% 0.01 N ACQUITY
Ultra Performance Liquid Chromatography Stephan Koza, Paula Hong, and Kenneth J. Fountain Waters Corporation, 34 Maple Street, Milford, MA, USA & SEC 2010 2 8 5 2030 4 3 8 1982 2009 131 USP EPHMW USP34
UPC 2 Baiba Cabovska, Michael D. Jones, and Andrew Aubin Waters Corporation, Milford, MA, USA UPC 2 ACQUITY UPC 2TM ACQUITY SQD Empower 3 UPC GC
UPC 2 Baiba Cabovska, Michael D. Jones, and Andrew Aubin Waters Corporation, Milford, MA, USA UPC 2 ACQUITY UPC 2TM ACQUITY SQD Empower 3 UPC 2 1-3 GC LC GC UltraPerformance Convergence Chromatography
Waters Sigma-Aldrich 1.0 mg/ml LC Waters Alliance HPLC ACQUITY UPLC H-Class Bio 30 cm Alliance HPLC UV ACQUITY UPLC TUV mm nm XBridge Protein B
HPLC 3. µm BEH Stephan Koza, Susan Serpa, Hua Yang, Edouard Bouvier, and Kenneth J. Fountain Waters Corporation, Milford, MA, USA HPLC 200 0 HPLC 2 2010 UPLC 200 SEC 1 UPLC SE-UPLC 2 µm BEH BEH 100% SE-UPLC
1 WSV SIR m/z Analyte RT (Min) SIR m/z Cone voltage (V) Ascorbic Acid (C).91 177 2 Thiamine (B1) 1.1 265 5 Nicotinic Acid (B3) 1.27 124 15 Pyridoxal (
ACQUITY UPLC H-Class ACQUITY QDa Mark E. Benvenuti, Dimple Shah, and Jennifer A. Burgess Waters Corporation, Milford, MA, USA MS ACQUITY QDa UPLC HPLC UV ACQUITY QDa LC EC 1925/26 CFR 21 HPLC 1 LC-MS ACQUITY
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
LC LC ACQUITY UPLC H-Class ACQUITY UPLC CSH C mm 1.7 µm : THF/ 2/8 A 1 mm / 4/6 THF 2 mg/ml THF/ 2 THF 2 ACQUITY UPLC CSH C 18
ACQUITY UPLC H-Class/QDa Nihon Waters K.K., Tokyo, Japan TAG 1 3 1 1 8 9 TAG TAG TAG TAG TAG UV UV APCI ESI MS TAG Sn-2 Sn-3 Sn-1 C18: ACQUITY UPLC CSH C 18 ACQUITY UPLC H-Class 1. ACQUITY QDa TAG ACQUITY
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35
HPLC UPLC JP UPLC システムによる 注入回数 3000 回以上 のルーチン製剤分析の実現 分析スループットの向上と使用溶媒量の削減 分析効率の向上 日本薬局方 (JP) は 薬事法第 41 条第一項の規定に基づき医薬品の品質を適性に担保するための公的な規範書であり 多くの医薬品の分析
JP システムによる 注入回数 3000 回以上 のルーチン製剤分析の実現 分析スループットの向上と使用溶媒量の削減 分析効率の向上 日本薬局方 (JP) は 薬事法第 41 条第一項の規定に基づき医薬品の品質を適性に担保するための公的な規範書であり 多くの医薬品の分析法は JP 法を基に開発されます また 一方では最新の技術を積極的に導入することによって 分析法の質を向上すると同時に効率性の向上
Sigma-Aldrich (Poole,Dorset,UK) LGC Standards(Teddington,Surrey,UK) 1 mg/ml Sigma-Aldrich Greyhound Chromatography(Brikenhead,UK) / Waters ACQUITY UPL
ACQUITY UPLC I-Class/Xevo TQD Mark Roberts and Michelle Wood Waters Corporation, MS Technologies Centre, Manchester, UK ACQUITY UPLC I-Class/Xevo TQD 2 2 MRM 178 / 950 MS ACQUITY UPLC/ACQUITY TQD 2 1-3
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
DCR-PC300K/IPK
3-084-945-02(1) 6 19 31 34 39 2003 Sony Corporation * b 2 3 6 19 31 4 34 39 5 \ 6 * * * 7 1 2 * 3 b 4 1 2 5 6 8 7 1 8 1 2 *, 9 2 7 3 8 * 4 9 5 6 z 10 10 1 2 3 1 1 11 2 * 2, 11 3 8 4 5 9 6 7 12 13 b,,,,,
zsj2017 (Toyama) program.pdf
88 th Annual Meeting of the Zoological Society of Japan Abstracts 88 th Annual Meeting of the Zoological Society of Japan Abstracts 88 th Annual Meeting of the Zoological Society of Japan Abstracts 88
88 th Annual Meeting of the Zoological Society of Japan Abstracts 88 th Annual Meeting of the Zoological Society of Japan Abstracts 88 th Annual Meeting of the Zoological Society of Japan Abstracts 88
_170825_<52D5><7269><5B66><4F1A>_<6821><4E86><5F8C><4FEE><6B63>_<518A><5B50><4F53><FF08><5168><9801><FF09>.pdf
88 th Annual Meeting of the Zoological Society of Japan Abstracts 88 th Annual Meeting of the Zoological Society of Japan Abstracts 88 th Annual Meeting of the Zoological Society of Japan Abstracts 88
EPSON LP-8900ユーザーズガイド
3 4 5 6 7 8 abc ade w p s 9 10 s s 11 p 12 p 13 14 p s 15 p s A B 16 w 17 C p 18 D E F 19 p w G H 20 A B 21 C s p D 22 E s p w 23 w w s 24 p w s 25 w 26 p p 27 w p s 28 w p 29 w p s 30 p s 31 A s B 32
ｎｓｇ０４－２８／ｋｙ２０８６８４３５６１０００４３０７７
δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!
124
[ ] [ ] 18 123 124 ( ) 125 126 127 128 5,683,062 2,306,419 18.2 14.0 12 5389 87 13 257 88 12 22 27 56.7 41.6 1 1.7 15 129 55 38.8 13.3 15 2004 15 1 3 84.8 29.3 1 23.9 38.0 10 10 35 35 15 5 56.5.31 55.4.1
2D-UPLC/MS Catalin Doneanu, Keith Fadgen, StJohn Skilton, Martha Stapels, and Weibin Chen Waters Corporation, Milford, MA, U.S. 4 5 HCP UPLC/MS E HCP
2D-UPLC/MS Catalin Doneanu, Keith Fadgen, StJohn Skilton, Martha Stapels, and Weibin Chen Waters Corporation, Milford, MA, U.S. 4 5 HCP UPLC/MS E HCP DNA 1 100 ppm HCPHCP HCP HCP 2008 EMA HCP 1 2006 HCP
HILIC UPLC/MS UPLC LC/ MS LC/MS HPLC 2-4 HPLC 4,5 HILIC / HILIC 80 ACQUITY UPLC Xevo QTof MS ACQUITY BEH HILIC HILIC TOF ESI 1.7 µm BEH HILIC UPLC HIL
HILIC UPLC/MS UPLC LC/ MS LC/MS HPLC 2-4 HPLC 4,5 HILIC / HILIC 80 ACQUITY UPLC Xevo QTof MS ACQUITY BEH HILIC HILIC TOF ESI 1.7 µm BEH HILIC UPLC HILIC UPLC HPLC 1 100 µl 900 µl 15 900 µl 500 µl 470 µl
MS Xevo G2 Q-Tof ESI+ 1 2 / pm-4 00 am 2 00 am # am # am #3 / pm am am #4 0.8 kv 20 V MS E ev MS E MASSLYNX
UPLC-Tof-MS E John Archer, 1 Paul Dargan, 1 David Wood, 1 Nayan Mistry, 2 and Michelle Wood 2 1 Guy s and St. Thomas NHS Foundation Trust, Clinical Toxicology, London, UK 2 Waters Corporation, MS Technologies
[ cortecs columns ] 可能性の限界に挑戦するµm 以下の ソリッドコアパーティクルカラム
![[ cortecs columns ] 可能性の限界に挑戦するµm 以下の ソリッドコアパーティクルカラム](/thumbs/40/20526183.jpg "[ cortecs columns ] 可能性の限界に挑戦するµm 以下の ソリッドコアパーティクルカラム")
[ cortecs columns ] 可能性の限界に挑戦するµm 以下の ソリッドコアパーティクルカラム C8 C8+ HILIC 究極のカラム効率と 性能を実現する ソリッドコアパーティクル カラム µm 以下のパーティクルの性能を最大 限に発揮させるための独自の研究成果に より ウォーターズは粒子径 µm 以下 の UltraPerformance LC カラムファミリー に 新製品を追加しました.6
1
1 2 INDEX 3 4 5 6 7 8 60100150200 2 300 60 16 113 134 155 123 100 28 174 215 600 183 150 214 40 200 183 183 60 100 40 150 3 4 5 60 100 150 200 25 1150120 1150120 1150120 2640 1250120 1250120 1250120 200
BIT -2-
2004.3.31 10 11 12-1- BIT -2- -3-256 258 932 524 585 -4- -5- A B A B AB A B A B C AB A B AB AB AB AB -6- -7- A B -8- -9- -10- mm -11- fax -12- -13- -14- -15- s58.10.1 1255 4.2 30.10-16- -17- -18- -19-6.12.10
2 2 1?? 2 1 1, 2 1, 2 1, 2, 3,... 1, 2 1, 3? , 2 2, 3? k, l m, n k, l m, n kn > ml...? 2 m, n n m
2009 IA I 22, 23, 24, 25, 26, 27 4 21 1 1 2 1! 4, 5 1? 50 1 2 1 1 2 1 4 2 2 2 1?? 2 1 1, 2 1, 2 1, 2, 3,... 1, 2 1, 3? 2 1 3 1 2 1 1, 2 2, 3? 2 1 3 2 3 2 k, l m, n k, l m, n kn > ml...? 2 m, n n m 3 2
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
アプリケーションソフトウェアガイド PM2200C用
4013356-01 C01 1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Printed
ID POS F
01D8101011L 2005 3 ID POS 2 2 1 F 1... 1 2 ID POS... 2 3... 4 3.1...4 3.2...4 3.3...5 3.4 F...5 3.5...6 3.6 2...6 4... 8 4.1...8 4.2...8 4.3...8 4.4...9 4.5...10 5... 12 5.1...12 5.2...13 5.3...15 5.4...17
内科９６巻３号★／ＮＡＩ３‐１（第２２回試験問題）
µ µ α µ µ µ µ µ µ β β α γ µ Enterococcus faecalis Escherichia coli Legionella pneumophila Pseudomonas aeruginosa Streptococcus viridans α β 正解表正解記号問題 No. 正解記号問題 No. e(4.5) 26 e 1 a(1.2) 27 a 2
筆王 for NEC
2 d 3 4 5 q w e r w e r q 6 q w q e 7 8 9 q q w w q w q w 10 11 12 q w 13 e q w e 14 q w q w e 15 r e 16 17 18 q w e 20 r q w t y q w e 21 u v v i o 22 !0!1!2 23 q w e 24 q w q w e e r y 25 q q w w q
3/4/8:9 { } { } β β β α β α β β
α β : α β β α β α, [ ] [ ] V, [ ] α α β [ ] β 3/4/8:9 3/4/8:9 { } { } β β β α β α β β [] β [] β β β β α ( ( ( ( ( ( [ ] [ ] [ β ] [ α β β ] [ α ( β β ] [ α] [ ( β β ] [] α [ β β ] ( / α α [ β β ] [ ] 3
2 7 ( ) µ JAJP.qxp
Agilent 1200 LC Our measure is your success. products applications software services - 4 90,000-20 HPLC - UV-Vis ELSD LC/MS - - Agilent 1200 LC (RRLC) 1 RRLC Agilent 1200 LC 2 2 ZORBAX HT 1.8 µm Poroshell
[ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2
![[ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2](/thumbs/91/106196485.jpg "[ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2")
N [ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2 [ GLYC AN ANALYSIS SLUTINS ] インタクトプロテイン解析のワークフロー 糖タンパク質 Intact mab Mass Check スタンダード LC 分析カラムにインジェクション UV 検出による
n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m
![n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m](/thumbs/94/118912662.jpg "n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m")
1 1 1 + 1 4 + + 1 n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m a n < ε 1 1. ε = 10 1 N m, n N a m a n < ε = 10 1 N
A-13 H S SH 3 H H H H d. H HSH 4 I F F 5 H NH 3 d. 6 H H H H H H H 7 H H H d. H H H H H F H H d. H H H N H 3 H d. e. NH 4 f. N g. N h. N
1 1 8 8 8 9 8 10 1 3 5 6d. 7 1 3 7 1 4 4Si 10 4 6S 10 6 N 5 P 10 5 1 5 1 4s 1 6 l HH HFd. l 1 7 Kl l 1 9 H H e. H F f. H 3 Li H 3 NH g. I l d. H 3 l h. H N H 1 10 LiH HF LiH 1 11 d. 1 14 H H H H H H H
まえがき
JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------
ネットショップ・オーナー２ ユーザーマニュアル
1 1-1 1-2 1-3 1-4 1 1-5 2 2-1 A C 2-2 A 2 C D E F G H I 2-3 2-4 2 C D E E A 3 3-1 A 3 A A 3 3 3 3-2 3-3 3-4 3 C 4 4-1 A A 4 B B C D C D E F G 4 H I J K L 4-2 4 C D E B D C A C B D 4 E F B E C 4-3 4
/9/ ) 1) 1 2 2) 4) ) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x ) x 2 8x + 10 = 0
1. 2018/9/ ) 1) 8 9) 2) 6 14) + 14 ) 1 4 8a 8b) 2 a + b) 4) 2 : 7 = x 8) : x ) x ) + 1 2 ) + 2 6) x + 1)x + ) 15 2. 2018/9/ ) 1) 1 2 2) 4) 2 + 6 5) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x 2 15 12
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
ありがとうございました
- 1 - - 2 - - 3 - - 4 - - 5 - 1 2 AB C A B C - 6 - - 7 - - 8 - 10 1 3 1 10 400 8 9-9 - 2600 1 119 26.44 63 50 15 325.37 131.99 457.36-10 - 5 977 1688 1805 200 7 80-11 - - 12 - - 13 - - 14 - 2-1 - 15 -
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
公務員人件費のシミュレーション分析
47 50 (a) (b) (c) (7) 11 10 2018 20 2028 16 17 18 19 20 21 22 20 90.1 9.9 20 87.2 12.8 2018 10 17 6.916.0 7.87.4 40.511.6 23 0.0% 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2.0% 4.0% 6.0% 8.0%
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 A B (A/B) 1 1,185 17,801 6.66% 2 943 26,598 3.55% 3 3,779 112,231 3.37% 4 8,174 246,350 3.32% 5 671 22,775 2.95% 6 2,606 89,705 2.91% 7 738 25,700 2.87% 8 1,134
橡hashik-f.PDF
1 1 1 11 12 13 2 2 21 22 3 3 3 4 4 8 22 10 23 10 11 11 24 12 12 13 25 14 15 16 18 19 20 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 144 142 140 140 29.7 70.0 0.7 22.1 16.4 13.6 9.3 5.0 2.9 0.0
198
197 198 199 200 201 202 A B C D E F G H I J K L 203 204 205 A B 206 A B C D E F 207 208 209 210 211 212 213 214 215 A B 216 217 218 219 220 221 222 223 224 225 226 227 228 229 A B C D 230 231 232 233 A
1
1 2 3 4 5 (2,433 ) 4,026 2710 243.3 2728 402.6 6 402.6 402.6 243.3 7 8 20.5 11.5 1.51 0.50.5 1.5 9 10 11 12 13 100 99 4 97 14 A AB A 12 14.615/100 1.096/1000 B B 1.096/1000 300 A1.5 B1.25 24 4,182,500
05[ ]戸田(責)村.indd
![05[ ]戸田(責)村.indd](/thumbs/91/106164845.jpg "05[ ]戸田(責)村.indd")
147 2 62 4 3.2.1.16 3.2.1.17 148 63 1 3.2.1.F 3.2.1.H 3.1.1.77 1.5.13 1 3.1.1.05 2 3 4 3.2.1.20 3.2.1.22 3.2.1.24 3.2.1.D 3.2.1.E 3.2.1.18 3.2.1.19 2 149 3.2.1.23 3.2.1.G 3.1.1.77 3.2.1.16 570 565 1 2
新たな基礎年金制度の構築に向けて
[ ] 1 1 4 60 1 ( 1 ) 1 1 1 4 1 1 1 1 1 4 1 2 1 1 1 ( ) 2 1 1 1 1 1 1 1996 1 3 4.3(2) 1997 1 65 1 1 2 1/3 ( )2/3 1 1/3 ( ) 1 1 2 3 2 4 6 2.1 1 2 1 ( ) 13 1 1 1 1 2 2 ( ) ( ) 1 ( ) 60 1 1 2.2 (1) (3) ( 9
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
EPSON LP-8900スタートアップガイド
1 2 3 4 5 6 7 8 4020009-01 F04 abc ade abc 1 abc ade 2 ade ade 3 4 w s A B C D E s s s s s s s s s 5 6 s 7 8 s s 9 10 w 700mm 200mm 400mm 878mm 200mm *1 720mm 200mm 1354mm w 11 abc w B A C w 12 D w s
24 2.オゾン層破壊 5.有害物質状態 6.都市環境質 7.生物多様性 14.特物質資源 2011 i ii iii iv v vi vii viii 2 3 4 5 6 7 ブラジル 1.2% 南アフリカ 1.3% インドネシア 1.3% オーストラリア 1.4% メキシコ 1.4% サウジアラビア 1.4% カナダ 1.8% イラン 1.8% 韓国 1.8% その他 20.5%
untitled
-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5
untitled
NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.
外因性内分泌攪乱化学物質調査暫定マニュアル（水質、底質、水生生物）
p,p -DDT p,p -DDE p,p -DDD trans- cis- trans- cis- (PBB) (BaP) 25ng/L 5µg/kg GC/MS-SIM GC/MS-SIM GC/MS-SIM GC/MS-SIM (2-, 3-, 4- ) (4,4'- ) p,p'-ddt- 13 C 12 HCB- 13 C 6 BaP-d 12 -d10 -d 10 p- -d 14 1000
